Team profiles

Professor Nicholas Barnes

Professor Nicholas Barnes

Qualifications

BSc (Hons) Medical Science, 1985
PhD Neuropharmacology, 1988
Fellow of the British Pharmacological Society, 2012

Professor Barnes’ principal research interest is translational neuropharmacology and along with Professor Ann Logan and Professor Tony Belli he founded the Translational Neurotrauma Research Group at the University of Birmingham.

Professor Barnes has published over 130 research papers giving rise to an h-index of 40 (including being the Principal Author of the most highly cited research paper from the University of Birmingham).

Professor Barnes is Chairman of the International Union of Basic and Clinical Pharmacology (IUPHAR) Nomenclature Committee for 5-HT Receptors, a Councillor of the International Society for Serotonin Research and a Fellow of the British Pharmacological Society.

He is also Editor-in-Chief for the international journal Frontiers in Neuropharmacology and holds Honorary Professorships at the University of Melbourne and the University of Siena.

Professor Barnes is also the Principal Founder of Celentyx Ltd (www.celentyx.com); a venture capital financed research and development pharmaceutical company (the company is based at the Birmingham Research Park).

Research from Professor Barnes’ academic laboratory has also generated a number of licensing deals for the University of Birmingham.

To further help commercialisation and knowledge transfer activities, Professor Barnes established the External Commercialisation Board (www.birmingham.ac.uk/mds-ecb) that is populated with highly experienced professionals from his network covering a broad range of expertise that provides strategic and operational advice relevant to third stream activities.

Professor Nicholas Barnes’s publications